| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| T655723-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $812.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Protected from light,Desiccated,Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research In Vitro TMX-201 is more potent cytokine inducer than Imiquimod (HY-B0180) in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg . TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects . TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:TLR7 |
| Canonical SMILES | O=C(N(C1=NC(OCCOC)=N2)CC3=CC=C(C=C3)C(NCCOP(OC[C@@H](COC(CCCCCCC/C=C\\CCCCCCCC)=O)OC(CCCCCCC/C=C\\CCCCCCCC)=O)(O)=O)=O)NC1=C2N |
|---|---|
| Molecular Weight | 1085.36 |
Enter Lot Number to search for COA:
